Gilead Sciences, Inc. (GILD)
After hours:
| Previous Close | 66.17 |
| Open | 66.30 |
| Bid | 65.67 x 700 |
| Ask | 68.62 x 100 |
| Day's Range | 65.21 - 66.43 |
| 52 Week Range | 64.33 - 87.87 |
| Volume | |
| Avg. Volume | 6,879,542 |
| Market Cap | 81.827B |
| Beta (5Y Monthly) | 0.23 |
| PE Ratio (TTM) | 182.44 |
| EPS (TTM) | 0.36 |
| Earnings Date | Aug 08, 2024 |
| Forward Dividend & Yield | 3.08 (4.69%) |
| Ex-Dividend Date | Jun 14, 2024 |
| 1y Target Est | 81.29 |
Business WireGilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
FOSTER CITY, Calif., May 22, 2024--Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, June 5-8, 2024 in Milan, Italy. Key findings from more than 25 abstracts will include:
ZacksHere is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Gilead (GILD). This makes it worthwhile to examine what the stock has in store.
Business WireInvestigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
FOSTER CITY, Calif., May 18, 2024--Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements in markers of cholestasis and reduced inflammation. Additional findings demonstrate that seladelpar can help reduce pruritus (itch) in people living with primary biliary cholangitis (PBC). There are cu
